Mazdutide 9 mg cuts weight 16.65% at 60 weeks in GLORY-2

The wire

1. 01The Phase 3 GLORY-2 trial tested once-weekly 9 mg mazdutide in Chinese adults with obesity, reporting 16.65% body weight reduction at 60 weeks versus 1.50% with placebo.
2. 02The result adds a GLP-1/glucagon dual agonist to the incretin field and signals competitive pressure in the Chinese obesity market.
3. 03Gastrointestinal adverse events were common, and the trial enrolled a Chinese population, limiting direct generalisation to other groups.

From the source

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.